ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 7.6 | 0.9 | 8.4 |
| Other income | 0.1 | 0.1 | 0.2 |
| Total income | 7.7 | 0.9 | 8.6 |
| Profit before exceptional items & tax | 0.5 | 0.1 | 0.3 |
| Profit before tax | 0.5 | 0.1 | 0.3 |
| Net profit | 0.2 | 0.1 | 0.2 |
| Operating margin | 6.5% | 11.1% | 3.5% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +0.00% |
|---|---|
| Net profit, quarter on quarter | +100.00% |
| Revenue, year on year | -9.50% |
BSE results filing, NSE: BIOFILCHEM. Figures extracted from the filing.
Biofil Chemicals & Pharmaceuticals Ltd: key numbers
- Share price
- ₹31.10
- Market cap
- ₹50.61 Cr
- Revenue (annual)
- ₹28.40 Cr
- Net profit (annual)
- ₹2.79 Cr
- P/E (TTM)
- 104.5×Sector 43.8×
- Promoter holding
- 46.79%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Biofil Chemicals & Pharmaceuticals Ltd
All →Biofil Chemicals & Pharmaceuticals Board Meeting Date
Biofil Chemicals intimates that its Board will meet on 14 Nov 2026 to approve unaudited Q1/H1 FY27 results. No financial figures or other material outcomes are disclosed yet.
Biofil Chemicals & Pharmaceuticals Other Announcement
The company submitted a certificate under Regulation 74(5) of SEBI (DP) Regulations for the quarter ended 30th September 2026, confirming compliance with depository norms.
Biofil Chemicals & Pharmaceuticals Management Change
Biofil Chemicals & Pharmaceuticals shareholders approved the continuation of Mr. Ashok Kumar Ramawat as a Non-Executive Independent Director, despite him exceeding 75 years of age.
Biofil Chemicals & Pharmaceuticals Annual General Meeting
Biofil Chemicals and Pharmaceuticals Limited held its 41st Annual General Meeting on 23rd September 2026. Members transacted routine business, including adoption of financial statements and director re-appointments.
Biofil Chemicals & Pharmaceuticals Other Announcement
Biofil Chemicals is notifying shareholders with unregistered email addresses about how to access the Annual Report and AGM Notice, per Regulation 36(1)(b) compliance requirements.
Biofil Chemicals & Pharmaceuticals Annual Report
Biofil Chemicals and Pharmaceuticals Limited has submitted its Integrated Annual Report for FY 2025-26. The 41st Annual General Meeting is scheduled for September 23, 2026.